Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC)
Brief Summary: The purpose of this study is to evaluate an investigational treatment for interstitial cystitis. Interstitial cystitis is a chronic bladder disease that includes the following symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and bladder discomfort relieved by voiding.

Presently, there is no cure for interstitial cystitis. The response to current treatments is poor. Patients with interstitial cystitis have a poorer quality of life. The cause of interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for improving the symptoms of patients with interstitial cystitis. Humira® is an injectable anti-inflammatory medication that has been available for use since December 31, 2002. Humira® has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial cystitis. This study will evaluate an investigational use of Humira® for the treatment of interstitial cystitis.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
B: Arm Label: Bladder instillation WITH triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder instillation WITH triamcinolone acetonide | Arm Label: Bladder instillation WITHOUT triamcinolone acetonide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bladder instillation WITHOUT triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITH triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITH triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITHOUT triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITHOUT triamcinolone acetonide
C: Arm Label: Global Therapeutic Massage (GTM); Type: SHAM_COMPARATOR; Interventions: Other: Global Therapeutic Massages (GTM) | Arm Label: Myofascial Tissue Manipulation (MTM); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial Tissue Manipulation (MTM) | Intervention Type: OTHER; Name: Global Therapeutic Massages (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial Tissue Manipulation (MTM); Assigned to Arm(s): Myofascial Tissue Manipulation (MTM)
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: Inactive drug; Type: PLACEBO_COMPARATOR; Interventions: Other: inactive drug | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: OTHER; Name: inactive drug; Assigned to Arm(s): Inactive drug

Answer: D